Shield Therapeutics (STX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 3.95p
   
  • Change Today:
      0.000p
  • 52 Week High: 12.20p
  • 52 Week Low: 3.82p
  • Currency: UK Pounds
  • Shares Issued: 1,069.91m
  • Volume: 2,914,330
  • Market Cap: £42.26m
  • Beta: 0.03

STX Overview

Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.

1 Day Chart (03-08-2026)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -20.2% n/a
ROCE 262.5%  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 1.6 n/a
Pr/Book n/a  
Latest F'cast
Revenue 54.4% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

STX Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 1.52 (19.91) (10.00)p n/a n/a n/a n/a 0.0%
31-Dec-22 5.50 (49.43) (21.00)p n/a n/a n/a n/a 0.0%
31-Dec-23 13.09 (32.38) (5.00)p n/a n/a n/a n/a 0.0%
31-Dec-24 32.18 (26.56) (3.00)¢ n/a n/a n/a n/a 0.0%
31-Dec-25 49.70 (17.14) (2.00)¢ n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

STX Company Announcements

Total Voting Rights 03-Aug-2026 12:02 RNS
Q2 and H1 2026 Trading Update 30-Jul-2026 07:00 RNS
ACCRUFeR® Phase 3 pediatric trial published 28-Jul-2026 07:00 RNS

STX ShareCast News

Shield Therapeutics reports positive Q1 earnings 01-May-2026 ShareCast
Shield's Accrufer MA application accepted in China 03-Mar-2026 ShareCast
Total Voting Rights 02-Jan-2026 ShareCast

Latest STX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

STX Market Data

Currency UK Pounds
Share Price 3.95p
Change Today 0.000p
% Change 0.00 %
52 Week High 12.20p
52 Week Low 3.82p
Volume 2,914,330
Shares Issued 1,069.91m
Market Cap £42.26m
Beta 0.03

STX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
12.49% below the market average12.49% below the market average12.49% below the market average12.49% below the market average12.49% below the market average
70.73% above the sector average70.73% above the sector average70.73% above the sector average70.73% above the sector average70.73% above the sector average
Price Trend
58.74% above the market average58.74% above the market average58.74% above the market average58.74% above the market average58.74% above the market average
77.27% above the sector average77.27% above the sector average77.27% above the sector average77.27% above the sector average77.27% above the sector average
Income Not Available
Growth
64.03% above the market average64.03% above the market average64.03% above the market average64.03% above the market average64.03% above the market average
79.31% above the sector average79.31% above the sector average79.31% above the sector average79.31% above the sector average79.31% above the sector average

STX Dividends

No dividends found

Trades for 03-Aug-2026

Time Volume / Share Price
16:35 11,448 @ 3.95p
16:35 11,448 @ 3.95p
16:20 31,381 @ 3.84p
16:13 350,000 @ 3.82p
16:11 500,000 @ 3.86p

STX Key Personnel

CEO Anders Lundstrom

Top of Page